Cancer52

"Cancer52 is once again delighted to support the QiC Oncology awards and to be involved in the judging process. Awards such as this can help to raise the profile of best practice, influence and inspire others, and most importantly improve outcomes for patients. Our hope is that Cancer52's involvement in these awards helps raise the profile of rare and less common cancers, and encourages entries from within this part of the cancer community in the future."

Jane Lyons, CEO Cancer52

QiC Oncology 2016 partner:
Bristol-Myers Squibb
Supported by: